NCT02631928已完成1 期
Single-center, Randomized, Double-blind, 2-treatment, 2-period Crossover Trial in Healthy Subjects to Demonstrate PK Bioequivalence and to Compare the PD Properties of Julphar Insulin 30/70 and Huminsulin® Profil III
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 73
- 试验地点
- 1
- 主要终点
- PK: AUCins.0-24, harea under the serum insulin concentration curve from 0-24 hours
研究概览
简要总结
This study in healthy volunteers aims to demonstrate similar PK and PD properties of the new human biphasic insulin, Julphar Insulin 30/70 and an already approved reference insulin, Huminsulin® Profil III. All participants will receive both study treatments on two separate dosing days.
详细描述
Daily injections of insulin is a necessity for many patients with diabetes mellitus in order to treat hyperglycaemia. Julphar Insulin 30/70 and Humininsulin® Profil III are both biphasic insulins, i.e. consist of a mixture of short-acting soluble insulin and intermediate-acting isophane insulin. The new insulin, Julphar Insulin 30/70, is biosimilar to Huminsulin® Profil III. Demonstration of similar absorption (PK) and effects (PD) are necessary to achieve market approval of Julphar Insulin 30/70.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedures that would not have been performed during normal management of the subject).
- •Healthy male subject.
- •Age between 18 and 55 years, both inclusive.
- •Body Mass Index (BMI) between 18.5 and 28.0 kg/m^2, both inclusive.
- •Fasting plasma glucose concentration <= 100 mg/dL.
排除标准
- •Known or suspected hypersensitivity to IMPs or related products.
- •Previous participation in this trial. Participation is defined as randomised.
- •Receipt of any medicinal product in clinical development within 3 months before screening.
- •Any history or presence of cancer except basal cell skin cancer or squamous cell skin cancer as judged by the Investigator.
- •Any history or presence of clinically relevant cardiovascular, pulmonary, respiratory, gastrointestinal, hepatic, renal, metabolic, endocrinological haematological, dermatological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness as judged by the Investigator.
- •Surgery within 12 weeks before the start of the study or blood donation of more than 500 mL (or considerable blood loss) or plasma donation within the last 3 months.
- •Increased risk of thrombosis, e.g., subjects with a history of deep leg vein thrombosis or family history of deep leg vein thrombosis, as judged by the Investigator.
- •Clinically significant abnormal values for haematology, biochemistry, coagulation, or urinalysis as judged by the Investigator.
- •Supine blood pressure (BP) at screening (after resting for 5 minutes in a supine position) outside the range of 90 to 140 mmHg for systolic BP or 50 to 90 mmHg for diastolic BP (excluding white-coat hypertension; therefore, if a repeated measurement shows values within the range, the subject can be included in the trial) and/or resting supine pulse < 50 beats per minute.
- •Clinically significant abnormal standard 12-lead electrocardiogram (ECG) after 5 minutes resting in supine position at screening, as judged by the Investigator.
- •Any disease or condition that, in the opinion of the Investigator, would represent an unacceptable risk for the subject's safety.
- •Positive to the screening test for Hepatitis Bs antigen or Hepatitis C antibodies and/or a positive result to the test for HIV-1/2 antibodies or HIV-1 antigen.
- •History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.
- •Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol.
- •Any medication (prescription and non-prescription drugs) within 14 days before first trial drug administration and/or anticoagulant therapy, with the exception of stable treatment with thyroid hormones, paracetamol and ibuprofen for occasional use to treat pain.
- •Significant history of alcoholism or drug abuse as judged by the Investigator or consuming more than 21 units of alcohol per week (one unit of alcohol equals about 330 mL of beer, one glass of wine of 120 mL, or 40 mL spirits).
- •A positive result in the alcohol and/or urine drug screen at the screening visit.
- •Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day) who is not able or willing to refrain from smoking and use of nicotine substitute products 1 day before and during the inpatient period.
- •Subject with mental incapacity or language barriers precluding adequate understanding or cooperation or who, in the opinion of the Investigator, should not participate in the trial.
- •Potentially noncompliant or uncooperative during the trial, as judged by the Investigator.
研究组 & 干预措施
Julphar Insulin 30/70
Experimental
human biphasic insulin, 100 IU/mL, single subcutaneous injection of 0.6 IU/ kg body weight
干预措施: human biphasic insulin (Drug)
Huminsulin® Profil III
Active Comparator
human biphasic insulin, reference, 100 IU/mL, single subcutaneous injection of 0.6 IU/ kg body weight
干预措施: human biphasic insulin, reference (Drug)
结局指标
主要结局
PK: AUCins.0-24, harea under the serum insulin concentration curve from 0-24 hours
时间窗: 24 hours
PK: Cins.max, maximum observed insulin concentration
时间窗: 24 hours
24 hours
次要结局
- PK: t½, terminal serum elimination half-life calculated as t½=ln2/λz(24 hours)
- PK: λz, terminal elimination rate constant of insulin(24 hours)
- PD: AUCGIR.0-6h, AUCGIR.0-12h, areas under the glucose infusion rate curve in the indicated time-intervals(12 hours)
- PD: Onset of action, time from trial product administration until blood glucose concentration has decreased at least 5 mg/dL from baseline(24 hours)
- PK: AUCins.0-6h, AUCins.0-12, areas under the serum insulin concentration curve in the indicated time intervals(12 hours)
- PK: AUCins.0-∞, area under the serum insulin concentration-time curve from 0 hours to infinity(24 hours)
- PK: tmax, time to maximum observed serum insulin concentration(24 hours)
- PD: AUCGIR.0h-last, area under the glucose infusion rate curve from 0 hours until the end of clamp(24 hours)
- PD: GIRmax, maximum observed glucose infusion rate(24 hours)
- Local tolerability findings(dosing period, approx.up to 39 days for each subject)
- PD: tGIR.max, time to maximum glucose infusion rate(24 hours)
- Adverse events(from the first trial drug administration until the final examination)
- Physical examination findings(from screening until final examination, approx.up to 60 days for each subject)
- Laboratory safety parameters(from screening until final examination, approx.up to 60 days for each subject)
- Changes in vital signs(from screening until final examination, approx.up to 39 days for each subject)
- Changes in Electrocardiogram recordings(from screening until final examination, approx.up to 60 days for each subject)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin N and Huminsulin® BasalDiabetes MellitusNCT02634528Julphar Gulf Pharmaceutical Industries85
已完成
1 期
Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics of Julphar Insulin R and Huminsulin® NormalDiabetes MellitusNCT02634515Julphar Gulf Pharmaceutical Industries26
招募中
1 期
Comparative PK, Safety, Tolerability, Immunogenicity, and PD Profile Study of TUR03 and Soliris in Healthy ParticipantsHealthyNCT05863442Turgut Ardika PTY LTD120
已完成
2 期
Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects Without Diabetes MellitusOverweight and ObesityNCT06532578Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.240
终止
3 期
Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®MelanomaNCT06587451Sandoz52